Considerations for Regulatory Oversight of Clinical Trials in the COVID-19 Pandemic, 5 June 2020
Gov't Doc #
MetadataShow full item record
This document provides national regulatory authorities (NRAs) with guidance for the regulation of clinical trials (CTs) in order to promote the investigation and use of safe and efficacious medicines and other health technologies that meet health needs during the COVID-19 pandemic.1 Well-conducted, blinded randomized controlled trials (RCTs) are considered the gold standard of clinical research and constitute the backbone of the procedure for the authorization of new drugs by drug regulatory agencies. CT regulation is focused on protecting the safety, wellbeing and rights of human subjects, ensuring trials are adequately designed to meet sound scientific objectives, and preventing fraud and falsification of data. During the COVID-19 pandemic, there is a moral urgency to conduct CTs that are not only ethically and scientifically rigorous, but that are also done expeditiously. The authorization and control of clinical trials considers ethical and scientific aspects that, according to the governance model defined by each country, assigns roles and responsibilities to various institutions, the most relevant being NRAs, research ethics committees, and, perhaps, other agencies such as the Ministry of Health and/or those with science and technology remits. These institutions must articulate and develop the requirements, guidelines, procedures and forms necessary to align with national, regional, and international guidelines, reflecting the principles enshrined in the Declaration of Helsinki, the International Ethical Guidelines for Health-related Research Involving Humans of the Council of International Organizations of Medical Sciences (CIOMS), The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), those of good clinical practices of the World Health Organization (WHO), and Pan American Health Organization (PAHO) guidance for ethics review and oversight during a pandemic...
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO
Showing items related by title, author, creator and subject.
Template and operational guidance for the ethics review and oversight of COVID-19-related research, 15 April 2020 Pan American Health Organization; Health Systems and Services (HSS) (Washington, D.C., PAHO, 2020-04-15)As part of the response to the COVID-19 pandemic, health research has proliferated. Clinical trials and other studies with human participants are being conducted to find efficacious treatments and vaccines for COVID-19. ...
Emergency Use of Unproven Interventions Outside of Research. Ethics Guidance for the COVID-19 Pandemic, 25 June 2020 Pan American Health Organization; Health Systems and Services (HSS) (Washington, D.C., PAHO, 2020-06-25)The COVID-19 pandemic presents us with the moral urgency to conduct rigorous research as soon as possible to produce evidence about the safety and efficacy of interventions to treat or prevent COVID-19. However, as in ...
Pan American Health Organization; Family, Health Promotion and Life Course (FPL) (Washington, D.C., PAHO, 2020-06-03)This document presents a brief summary of vaccines in development for COVID-19. At the end of 2019, the new SARS-CoV-2 coronavirus emerged. Although there is not yet a vaccine against this virus, the field of research for ...